Search

Displaying results 3621 - 3630 of 8575 in total
  1. Drug

    Reposal

    go.drugbank.com/drugs/DB13805
    Experimental

    Reposal is a barbiturate derivative invented in the 1960s in Denmark that has sedative, hypnotic and anticonvulsant properties. It was used primarily in the treatment of insomnia.

  2. Drug

    Trilostane

    go.drugbank.com/drugs/DB01108
    ApprovedVet approvedWithdrawn

    It was withdrawn from the United States market in April 1994.

  3. Drug

    AS-8112

    go.drugbank.com/drugs/DB09207
    Experimental

    It has been shown to exert potent antiemetic effects in animal studies and has been investigated for potential medical use. … AS-8112 is a synthetic compound that acts as a selective antagonist at the dopamine receptor subtypes D2 and D3, and the serotonin receptor 5-HT3.

  4. Drug

    Trefoil Factor 2

    go.drugbank.com/drugs/DB15750
    Experimental

    The trefoil factor 2 (TFF2) peptide is a low-molecular weight protein and one of the three trefoil-motif-containing proteins. They are expressed predominantly in gastric tissues with the source for them being predominantly stromal cells,...

  5. Drug

    Itopride

    go.drugbank.com/drugs/DB04924
    Investigational

    Itopride is a dopamine D2 antagonist with acetylcholinesterase inhibitory actions.

  6. Drug

    Satraplatin

    go.drugbank.com/drugs/DB04996
    Investigational

    As an investigation drug, it has not yet received U.S. Food and Drug Administration (FDA) approval and is not available in retail pharmacies. … Satraplatin is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy.

  7. Drug

    Patupilone

    go.drugbank.com/drugs/DB03010
    Investigational

    Epothilone B is a 16-membered macrolide that mimics the biological effects of taxol.

  8. Drug

    BMS-564929

    go.drugbank.com/drugs/DB07286
    Experimental

    BMS-564929 is an investigational therapeutic agent built to be a selective androgen receptor modulator (SARM). … So far, it has been developed by Bristol-Myers Squibb for the symptomatic treatment of andropause.

  9. Drug

    Dihydrostreptomycin

    go.drugbank.com/drugs/DB11512
    ApprovedVet approvedWithdrawn

    In humans, the use of dihydrostreptomycin has been associated with ototoxicity. The FDA withdrew its approval for the use of all drug products containing dihydrostreptomycin sulfate.[L43942]

  10. Drug

    Arylacenamide

    go.drugbank.com/drugs/DB05792
    Experimental

    Arylacenamide (SR31747) is a peripheral [sigma] ligand that binds four proteins in human cells, i.e. SRBP-1, [sigma]-2, HSI and its relative SRBP-2. It is a dual agent with both immunomodulatory and antiproliferative activities.